6901 Stock Overview
Diamond Biofund Inc. is a venture capital firm specializing in early venture, mid venture, late venture and growth capital investments.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Diamond Biofund Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$39.50 |
| 52 Week High | NT$78.05 |
| 52 Week Low | NT$38.50 |
| Beta | 0 |
| 1 Month Change | -5.73% |
| 3 Month Change | -10.43% |
| 1 Year Change | -44.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6901 | TW Capital Markets | TW Market | |
|---|---|---|---|
| 7D | -2.2% | 4.9% | -0.6% |
| 1Y | -44.6% | 17.6% | 29.2% |
Return vs Industry: 6901 underperformed the TW Capital Markets industry which returned 17.6% over the past year.
Return vs Market: 6901 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6901 volatility | |
|---|---|
| 6901 Average Weekly Movement | 4.1% |
| Capital Markets Industry Average Movement | 4.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6901 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6901's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 28 | Yolanda Wu | www.diamondbiofund.com/tc/index.htm |
Diamond Biofund Inc. is a venture capital firm specializing in early venture, mid venture, late venture and growth capital investments. The firm typically invest in Greater China markets with focus in biotechnology, new drug research and development, innovative and high precision medical equipment, innovative medical service technology or model, medical access, agricultural biotechnology and medical services. It invests in China, Taiwan and Hong Kong.
Diamond Biofund Inc. Fundamentals Summary
| 6901 fundamental statistics | |
|---|---|
| Market cap | NT$33.95b |
| Earnings (TTM) | -NT$2.58b |
| Revenue (TTM) | n/a |
-13.8x
P/S Ratio-13.0x
P/E RatioIs 6901 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6901 income statement (TTM) | |
|---|---|
| Revenue | -NT$2.44b |
| Cost of Revenue | NT$0 |
| Gross Profit | -NT$2.44b |
| Other Expenses | NT$143.89m |
| Earnings | -NT$2.58b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | 105.90% |
| Debt/Equity Ratio | 0% |
How did 6901 perform over the long term?
See historical performance and comparison